Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Cordis launches new PTA Balloon Catheter to treat PAD

Cordis Corporation is pleased to announce the launch of SLEEK® OTW Catheter, a new .014" Percutaneous Transluminal Angioplasty Balloon Catheter designed to help physicians save limbs and enhance patients' lives.

22 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

Cardiovascular Systems, Inc. has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA), and has begun a limited market release for the Stealth 360°™ Orbital PAD System. The Stealth 360° propels CSI into the forefront of treating peripheral arterial disease (PAD) with a simpler design that gives physicians complete control of device operation.

17 Mar 2011

St. Jude Medical achieves 2 million mechanical heart valve implant milestone

St. Jude Medical, Inc., a global medical device company, today announced that the company will celebrate the treatment of more than 2 million patients with its mechanical heart valve technology. This milestone, a landmark achievement for prosthetic heart valves, demonstrates the company's commitment to cardiac surgery and improving patient outcomes.

16 Mar 2011

Corindus begins CorPath Percutaneous Robotic-Enhanced Coronary Intervention Study trial

Corindus Vascular Robotics, a leading developer of precision vascular robotics, announced today that the clinical trial of its CorPath PRECISE has begun.

16 Mar 2011

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

14 Mar 2011

Scientists integrate stretchable electronics technology with balloon catheters for cardiac procedures

Cardiologists may soon be able to place sensitive electronics inside their patients' hearts with minimal invasiveness, enabling more sophisticated and efficient diagnosis and treatment of arrhythmias.

8 Mar 2011

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.

5 Mar 2011

Stockholm court rules in favour of Occlutech against AGA-St Jude Medical

Occlutech GmbH, a leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced that it has received a favourable court ruling from Stockholm, Sweden in the on-going patent litigation with AGA Medical -St Jude Medical.

5 Mar 2011

First artificial bronchus graft in a lung cancer patient successful

In a medical breakthrough French surgeons have grafted an artificial airway to save a lung afflicted by bronchial cancer in a 78-year-old man. The bronchi are the main tubes or airways used for taking air from the trachea to the two sides of the lung.

3 Mar 2011

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) has completed the first two transcatheter aortic valve implants (TAVI) ever achieved in Michigan. The procedures are a part of CVI's participation in the Medtronic CoreValve® U.S. Clinical Trial. This multi-state trial will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis.

2 Mar 2011

OrbusNeich's Sapphire II coronary dilatation catheter is now available in the market

OrbusNeich today announced that the next-generation Sapphire II coronary dilatation catheter is now commercially available, following CE Mark approval.

28 Feb 2011

Western Medical installs Toshiba's vascular X-ray system to provide efficiency during diagnostic procedures

To increase diagnostic capabilities and provide patients with the highest quality care, Western Medical Center Santa Ana has installed Toshiba America Medical Systems, Inc.'s Infinix VF-i bi-plane vascular X-ray system with Volume Navigation 3D roadmapping.

28 Feb 2011

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

28 Feb 2011

$MHI begins patient enrollment for new device to treat refractory angina$

MHI begins patient enrollment for new device to treat refractory angina

The interventional cardiology team at the Montreal Heart Institute recently began patient enrolment for a new device, the Neovasc Reducer, designed to treat patients suffering from refractory angina.

25 Feb 2011

Opsens completes pre-clinical EasyWire device study for measurement of FFR in coronary arteries

Opsens Inc. said today that its Medical Division has reached a significant milestone, successfully completing a pre-clinical animal study on the EasyWire device, designed to measure Fractional Flow Reserve in the evaluation of coronary lesions.

24 Feb 2011

InfraReDx to showcase LipiScan IVUS Coronary Imaging System at CRT 2011

InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.

24 Feb 2011

Xenogenics retains Emmes to assist with development, execution of its capital formation strategy

Xenogenics Corporation, a majority owned subsidiary of MultiCell Technologies, Inc., is pleased to announce it has retained the Emmes Group to assist with the development and execution of its capital formation strategy to help finance expanded human clinical trials of its Ideal BioStent.

24 Feb 2011

California researchers receive InHealth grant to evaluate device-intensive procedures

The Institute for Health Technology Studies has awarded a $263,000 grant to a research team at the University of California, Berkeley, to identify and analyze the strategies that hospital systems employ to evaluate and purchase implantable medical devices for cardiac, spinal, and orthopedic procedures.

23 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

Stent News and Research

Further Reading

Cordis launches new PTA Balloon Catheter to treat PAD

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

St. Jude Medical achieves 2 million mechanical heart valve implant milestone

Corindus begins CorPath Percutaneous Robotic-Enhanced Coronary Intervention Study trial

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

Scientists integrate stretchable electronics technology with balloon catheters for cardiac procedures

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

Stockholm court rules in favour of Occlutech against AGA-St Jude Medical

First artificial bronchus graft in a lung cancer patient successful

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

OrbusNeich's Sapphire II coronary dilatation catheter is now available in the market

Western Medical installs Toshiba's vascular X-ray system to provide efficiency during diagnostic procedures

Scripps Health offers genetic testing to patients with Hepatitis C

MHI begins patient enrollment for new device to treat refractory angina

Opsens completes pre-clinical EasyWire device study for measurement of FFR in coronary arteries

InfraReDx to showcase LipiScan IVUS Coronary Imaging System at CRT 2011

Xenogenics retains Emmes to assist with development, execution of its capital formation strategy

California researchers receive InHealth grant to evaluate device-intensive procedures

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News